Sionna Therapeutics, Inc.
SIONDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
SION Earnings Report
EPS Est: $-0.64 | FQ end 2026-06
How SION's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SION-719 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sionna Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Sionna Therapeutics, Inc.'s (SION) pipeline across Phase 2. Its lead program is SION-719 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sionna Therapeutics, Inc.'s next FDA catalyst?→
Sionna Therapeutics, Inc.'s (SION) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SION biotech catalysts?→
Add SION to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sionna Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.